Home:
PCU 4|2002: A
Oliver Sartor, BA, MD: Select publications
Select publications
Arai Y et al. Incidence of lymph node metastasis and its
impact on long-term prognosis in clinically localized prostate cancer.
Int J Urol 1998;5(5):459-65. Abstract
Bader P et al. Is a limited lymph node dissection an adequate
staging procedure for prostate cancer? J Urol 2002;168(2):514-8;discussion
518. Abstract
Berruti A et al. Changes in bone mineral density, lean
body mass and fat content as measured by dual energy X-ray absorptiometry
in patients with prostate cancer without apparent bone metastases
given androgen deprivation therapy. J Urol 2002;167(6):2361-7;discussion
2367. Abstract
Bissonette EA et al. Prostate specific antigen kinetics
at tumor recurrence after radical prostatectomy do not suggest a
worse disease prognosis in black men. J Urol 2001;166(4):1328-
31;discussion 1331-2. Abstract
Burkhard F et al. Reliability of preoperative values to
determine the need for lymphadenectomy in patients with prostate
cancer and meticulous lymph node dissection. Eur Urol 2002;42(2):84.
Abstract
Daniell HW. Osteoporosis due to androgen deprivation therapy
in men with prostate cancer. Urology 2001;58(2 Suppl 1):101-7.
Abstract
Fergany A et al. No difference in biochemical failure
rates with or without pelvic lymph node dissection during radical
prostatectomy in low-risk patients. Urology 2000;56(1):92-5.
Abstract
Fowler JE Jr et al. Race and cause-specific survival with
prostate cancer: Influence of clinical stage, Gleason score, age
and treatment. J Urol 2000;163(1):137-42. Abstract
Freedland SJ et al. Race is not an independent predictor
of biochemical recurrence after radical prostatectomy in an equal
access medical center. Urology 2000;56(1):87-91. Abstract
Hoffman RM et al. Racial and ethnic differences in advanced-stage
prostate cancer: TheProstate Cancer Outcomes Study. J Natl
Cancer Inst 2001;93(5):388-95. Abstract
Kiratli BJ et al. Progressive decrease in bone density
over 10 years of androgen deprivation therapy in patients with prostate
cancer. Urology 2001;57(1):127-32. Abstract
Link RE, Morton RA. Indications for pelvic lymphadenectomy
in prostate cancer. Urol Clin North Am 2001;28(3):491-8.
Abstract
Moyad MA. Complementary therapies for reducing the risk
of osteoporosis in patients receiving luteinizing hormone-releasing
hormone treatment/orchiectomy for prostate cancer: A review and
assessment of the need for more research. Urology 2002;59(4
Suppl 1):34-40. Abstract
Shackley DC et al. Staging laparoscopic pelvic lymphadenectomy
in prostate cancer. BJU Int 1999;83(3):260-4. Abstract
Smith MR. Osteoporosis during androgen deprivation therapy
for prostate cancer. Urology 2002;60(3 Suppl 1):79-85;discussion
86. Abstract
|
